News | December 19, 2025
ystral expands in India with new Bangalore facility, boosting team & local production
The expansion includes a larger technical and service team and increased local procurement
The expansion includes a larger technical and service team and increased local procurement
The state-of-the-art facility is expected to be commissioned over the next three years
GS-098, a first-in-class, humanized monoclonal antibody targeting the thyroid-stimulating hormone receptor, is designed to rapidly block the pathogenic activity of thyroid-stimulating autoantibodies
Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A
The move strengthens GBL’s clinical-stage presence in the United States
The combination also outperformed chemotherapy on another important secondary endpoint
Hansoh Pharma will receive an upfront payment in the low double-digit millions
India plays a critical role in Bristol Myers Squibb’s global strategy
Imsidolimab, an IgG4 IL-36 receptor antagonist, works by inhibiting IL-36 receptor signaling, directly addressing the deficiency in the IL-36RA regulator common in GPP patients
Subscribe To Our Newsletter & Stay Updated
